In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Gamida Cell (GMDA - Research Report), with a price target of $17.00. The company's shares opened today at $2.33.Butler covers the Healthcare sector, focusing on stocks such as Athira Pharma, ACADIA Pharmaceuticals, and Quoin Pharmaceuticals. According to TipRanks, Butler has an average return of -3.1% and a 41.65% success rate on recommended stocks. Gamida Cell has an analyst consensus of Strong Buy, with a price target consensus of $14.80, which is a 535.19% upside from current levels. In a report released on September 13, H.C.
https://www.tipranks.com/news/blurbs/jmp-securities-sticks-to-their-buy-rating-for-gamida-cell-gmda-2?utm_source=advfn.com&utm_medium=referral
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more Gamida Cell Charts.
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more Gamida Cell Charts.